Italia markets close in 7 hours 38 minutes

Supernus Pharmaceuticals, Inc. (0LB2.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
29,01-0,57 (-1,91%)
Al 03:11PM BST. Mercato aperto.

Supernus Pharmaceuticals, Inc.

9715 Key West Avenue
Rockville, MD 20850
United States
301 838 2500

Impiegati a tempo pieno612

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Jack A. KhattarFounder, Pres, CEO, Sec. & Director1,63M10,79M1961
Mr. Timothy C. DecSr. VP & CFO635,43kN/D1959
Dr. Padmanabh P. Bhatt Ph.D.Chief Scientific Officer & Sr. VP of Intellectual Property594,14k334,6k1957
Mr. Frank MottolaSr. VP of Quality, GMP Operations & Information Technology490,87kN/D1972
Dr. Jonathan Rubin M.D., MBASr. VP of R&D and Chief Medical Officer594,65kN/D1961
Mr. Kevin T. AndersonCompliance OfficerN/DN/D1962
Dr. Todd Horich M.B.A., Ph.D.Sr. VP of Marketing & Market AccessN/DN/DN/D
Mr. Taylor RaifordSr. VP of SalesN/DN/DN/D
Dr. Bryan A. Roecklein Ph.D.Sr. VP of Corp. Devel.N/DN/DN/D
Ms. Tami T. Martin Esq., R.N.Sr. VP of Regulatory AffairsN/DN/D1955
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.


Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di Supernus Pharmaceuticals, Inc. al 1 settembre 2023 è 6. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 7; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.